市場調查報告書
商品編碼
1240034
全球基因檢測市場——規模、測試、應用、技術、行業分析報告、國家展望、增長潛力、適用性、競爭市場份額和預測,2023-2032 年Genetic Testing Market Size, By Test, By Application, By Technology, Industry Analysis Report, Country Outlook, Growth Potential, Application Potential, Competitive Market Share & Forecast, 2023-2032 |
由於醫生越來越多地在臨床實踐中採用基因檢測,預計到 2032 年全球基因檢測市場將經歷強勁增長。
基因檢測在遺傳和腫瘤疾病中的廣泛應用,以及醫生在臨床治療中越來越多地使用基因檢測,預計將在預測期內推動市場擴張。
技術發展和新測試的可用性推動了基因檢測的需求,增加了患者對個性化藥物的偏好並加速了公司的發展。 此外,以基因檢測解決方案為重點的研發投入將在未來幾年推動市場擴張。 例如,英國政府已宣布超過 1.277 億美元用於促進新生兒罕見遺傳病的診斷。 還提供了額外的資金來提高癌症檢測的速度和準確性,並啟動解決健康差異的計劃。
基因檢測市場按檢測、應用、技術和區域進行細分。
根據測試,到 2032 年,預測測試部分的估值預計將超過 19 億美元。 技術進步和遺傳疾病日益流行將推動預測測試市場。 有影響力的渲染因素包括新型基因檢測方法和技術的發展,以及效率和準確性的提高。 例如,無創產前檢測 (NIPT) 和無細胞胎兒 DNA 檢測的引入將加速基因檢測的接受度並支持市場擴張。
從應用來看,隨著心肌病、心律失常和高膽固醇等遺傳性心血管疾病所佔比例的增加,預計未來幾年心血管疾病領域將顯著擴大。 此外,良好的心血管疾病檢測報銷有望推動這一領域的增長。
在技術方面,預計分子檢測領域在預測期內將顯著增長。 基因分型被認為有助於預後、疾病診斷、進展、治療選擇和反應以及遺傳特異性藥物靶標的鑑定。
按地區劃分,到 2032 年,歐洲基因檢測市場預計將佔據超過 98 億美元的業務份額。 該地區的市場增長歸因於專注於將先進技術融入基因檢測設備的行業巨頭的擴張。
Global Genetic Testing Market is set to experience robust growth through 2032 owing to the increasing adoption of genetic testing for clinical care by physicians. The growing use of genetic testing in genetic and oncology illnesses, as well as increased physician use of genetic tests in clinical treatment, is set to drive market expansion during the forecast timeframe.
The demand for genetic testing has been fueled by technological developments and the availability of new tests, which has raised patient preference for tailored medications and accelerated corporate growth. Furthermore, hefty investments in R&D studies focusing on genetic testing solutions would boost the market expansion in the coming years. Citing an instance, the government of UK announced more than USD 127.7 million to accelerate the diagnosis of rare genetic diseases in newborns. Besides, additional funding was offered to kickstart programs to improve the speed and accuracy of cancer detection and managing health inequalities.
The genetic testing market has been divided in terms of test, application, technology, and region.
Based on test, the predictive testing segment is expected to amass more than USD 1.9 billion valuation by 2032. Technological developments, combined with an increase in the prevalence of genetic illnesses, will drive the predictive testing market. High-impact rendering elements include the development of novel genetic testing methods and technologies, as well as improved efficiency and accuracy. The introduction of non-invasive prenatal testing (NIPT) or cell-free fetal DNA testing, for example, will accelerate the acceptance of genetic testing and support the market expansion.
With respect to application, the cardiovascular diseases segment is anticipated to expand significantly over the review years credited to the growing rates of inherited cardiovascular conditions including cardiomyopathy, arrhythmias, as well as high blood cholesterol. Moreover, good reimbursement provided for the detection of cardiovascular disorders is set to propel segmental growth.
In terms of technology, the molecular testing segment is poised to proliferate robustly through the forecast period. Genotyping can help with prognosis, disease diagnosis, and progression, as well as guide treatment options and response, and identify targets for gene-specific medicines.
From the regional perspective, the Europe genetic testing market is speculated to attain more than USD 9.8 billion business share by 2032. The regional market growth can be credited to the expanding presence of major players in the industry that are focusing on integrating advanced techniques within genetic testing equipment.